StockData
Beta Bionics, Inc. logo

Beta Bionics, Inc. (BBNX) stock

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 11/304% below fair value
$14.72−0.49 (-3.22%)

Close on Nov 17, 2026Market cap $800.28MP/E –Yield –

Beta Bionics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Beta Bionics's operating cash flow for the twelve months ending Sep 30, 2026 was -$59.37M. For fiscal 2025 it was -$50.93M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$50.93M–
FY2024Dec 31, 2024-$48.27M–
FY2023Dec 31, 2023-$32.45M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$12.29M–
Q2 FY2026Jun 30, 2026-$14.62M–
Q1 FY2026Mar 31, 2026-$23.83M–
Q4 FY2025Dec 31, 2025-$8.63M–
Q3 FY2025Sep 30, 2025-$8.73M–
Q2 FY2025Jun 30, 2025-$13.59M–
Q1 FY2025Mar 31, 2025-$19.98M–
Q4 FY2024Dec 31, 2024-$14.28M–
Q3 FY2024Sep 30, 2024-$9.61M–
Q2 FY2024Jun 30, 2024-$12.24M–
Q1 FY2024Mar 31, 2024-$12.14M–

More Beta Bionics figures

See a number that looks wrong?